Atorvastatin in polycystic ovary syndrome (PCOS)

Effect of atorvastatin on the metabolic syndrome of polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN24474824

Enrollment

Registered

2008-05-09

Start date

2006-07-13

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome (PCOS) Nutritional, Metabolic, Endocrine Ovarian dysfunction

Interventions

40 patients with polycystic ovary syndrome will be randomised to: 1. 20 patients treated with atorvastatin 20 mg 2. 20 patients treated placebo The tot

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. A diagnosis of PCOS was based on Rotterdam criteria 2. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, and androgen secreting tumours excluded by appropriate tests 3. Subjects were advised not to alter their usual dietary and exercise habits 4. Females aged 18 - 40 years

Exclusion criteria

Exclusion criteria: 1. No concurrent illness 2. Patients not wishing to allow disclosure to their GPs 3. Patients not on barrier or oral progesterone contraception

Design outcomes

Primary

Measure	Time frame
Improvement in biochemical hyperandrogenaemia, measured at baseline and after three months.	—

Secondary

Measure	Time frame
Improvement in insulin resistance, measured at baseline and after three months.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 21, 2026